Antibodies against PDAC- associated antigens are useful for early cancer diagnosis and therapy.

Tumor growth and immune responses against CEA and other tumor- associated antigens were determined.

Tumor- associated antigens have emerged as important immunotherapeutic targets in the fight against cancer.

An important issue for future immunologic treatments is the characterization of appropriate tumor- associated antigens.

This reactivity pattern suggested that CTLs recognized leukemia- associated antigens or hematopoietic minor histocompatibility antigens.

One form of immunotherapy uses chimeric antigen receptors (CAR) to target tumor- associated antigens.

The immunogenicity of these vaccines can be enhanced by co-expressing costimulatory molecules and tumor- associated antigens.

Previous studies have shown that melanoma patients develop an immune response to cell surface melanoma- associated antigens.

Identifying appropriate prostate cancer- associated antigens is critical to the development of immunologic treatments for prostate cancer.

There was diverse cytokine mRNA expression and IL-1 beta protein was restricted to cells expressing B-cell- associated antigens.

Chronic exposure to tumor- associated antigens inactivates cognate T cells, restricting the repertoire of tumor-specific effector T cells.

However, the immune system frequently fails to mount a successful defense against cancers despite vaccination with tumor- associated antigens.

Melanoma- associated antigens (MAGE)-A9 has been reported to play important roles in the development of human cancers.

Conversely, the reactivity of other T-cell associated antigens seemed to be very similar in AIDS-related and AIDS-unrelated NHLs.

The first is ipilimumab, an anti-CTLA-4 monoclonal antibody that enhances cellular immunity and reduces tolerance to tumor- associated antigens.

DCs are a critical component of immune responses in cancer primarily due to their ability to cross-present tumor- associated antigens.